Chimeric Antigen Receptors that Recognize BCMA/ CD269 for Treating Multiple Myeloma

Available for licensing are chimeric antigen receptors (CARs) that specifically target B-cell maturation antigen (BCMA, CD269), a protein that is highly expressed on the surface of multiple myeloma cells. Multiple myeloma is a malignancy of plasma cells. It is almost always incurable.


A CAR is a fusion protein that can recognize a specific protein on a tumor cell and activate an adaptive immune response to attack the tumor cell. When cultured with multiple myeloma cells in vitro, T-cells engineered to express the CARs were able to induce cell death in the myeloma cells. CARs currently are being evaluated in clinical trials as a promising new area of cancer therapy. The technology available for licensing includes vectors incorporating the CARs, as well as methods of destroying multiple myeloma cells using T-cells engineered to express a CAR. CRADA Opportunity: The National Cancer Institute, Experimental Transplantation and Immunology Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize chimeric antigen receptors to genetically-modify T cells to recognize BCMA/ CD269. For collaboration opportunities, please contact John Hewes, Ph.D. at hewesj@mail.nih.gov.

Source: http://www.ott.nih.gov/Technologies/abstractDetails.aspx?RefNo=2424

Hilary Swank Isla Fisher Ivana Bozilovic Ivanka Trump Izabella Miko